Gene Therapy Pionee | Adverum Biotechnologies leads in ocular gene therapies, with pivotal trials for wet AMD treatment progressing ahead of schedule, showcasing operational efficiency |
Safety Innovations | Explore Adverum's efforts to enhance treatment safety through lower doses and increased steroid exposure, potentially improving the therapeutic index |
Financial Tightrope | Delve into Adverum's financial challenges as it balances a $126 million cash position against the high costs of clinical trials, with analyst price targets ranging from $5 to $40 |
Market Dynamics | Learn how Adverum navigates a competitive landscape, facing challenges from emerging long-acting TKIs while targeting the substantial wet AMD treatment market |
Metrics to compare | ADVM | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipADVMPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −2.9x | −0.4x | |
PEG Ratio | 0.00 | −0.05 | 0.00 | |
Price/Book | 0.0x | 2.8x | 2.6x | |
Price / LTM Sales | 0.0x | 8.4x | 3.0x | |
Upside (Analyst Target) | 0.0% | 111.8% | 58.3% | |
Fair Value Upside | Unlock | 4.5% | 8.3% | Unlock |